Press release
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference
Mini-symposia to focus on long-term extension data for the Tyvaso® INCREASE study, the ralinepag phase 2 study, and the Orenitram® FREEDOM-EV study Poster
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nMini-symposia to focus on long-term extension data for the Tyvaso® INCREASE study, the ralinepag phase 2 study, and the Orenitram® FREEDOM-EV study\n\nPoster presentations touch on real-world treprostinil use, Tyvaso DPI™, and other treprostinil clinical studies\n\nUnited Therapeutics is hosting a sponsored symposium on PH-ILD and sponsoring the ATS 2022 Women’s Forum\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that eight posters and three mini-symposia across the company’s commercial and development portfolio will be presented at the 2022 American Thoracic Society (ATS) International Conference, taking place May 13-18, 2022, in San Francisco. In addition, the company is hosting a sponsored symposium on pulmonary hypertension associated with interstitial lung disease (PH-ILD) and is sponsoring the ATS 2022 Women’s Forum.\n\n“ATS 2022 will provide us with the opportunity to update the pulmonary hypertension community on long-term data with presentations on the INCREASE, FREEDOM-EV, and phase 2 ralinepag open label extension studies,” said Gil Golden, M.D., Ph.D., Chief Medical Officer of United Therapeutics. “This year’s conference will also allow us to feature poster presentations on Tyvaso DPI, the EXPEDITE study, the ADAPT registry, and real-world outcomes data for our treprostinil products.”\n\nMini-symposia include:\n\nMini-symposium, Sunday, May 15, 2:45 - 2:55 PM PT: A96 – Long-Term Data from Study APD811-007, an Open-Label Extension Study Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension. Presented by Elizabeth S. Klings, M.D., Boston University School of Medicine.\n\nMini-symposium, Sunday, May 15, 3:15 - 3:25 PM PT: A96 – Long-Term Efficacy of Oral Treprostinil in Subjects with Pulmonary Arterial Hypertension: FREEDOM-EV Open-Label Extension Study. Presented by R. James White, M.D., Ph.D., University of Rochester.\n\nMini-symposium, Monday, May 16, 3:35 - 3:45 PM PT: B96 - Long-Term Effects of Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Interstitial Lung Disease: The INCREASE Study Open-Label Extension. Presented by Aaron B. Waxman, M.D., Ph.D., Brigham and Women’s Hospital, Boston.\n\nPosters include:\n\nThematic poster session, Monday, May 16, 11:...